StockNews.com Initiates Coverage on Aptose Biosciences (NASDAQ:APTO)

Stock analysts at StockNews.com initiated coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a note issued to investors on Thursday. The brokerage set a “sell” rating on the biotechnology company’s stock.

APTO has been the topic of several other research reports. HC Wainwright restated a “buy” rating and set a $60.00 price target on shares of Aptose Biosciences in a research note on Wednesday, February 12th. Alliance Global Partners raised shares of Aptose Biosciences to a “strong-buy” rating in a research report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $112.00.

Aptose Biosciences Stock Performance

Shares of NASDAQ APTO opened at $3.32 on Thursday. The business has a 50 day simple moving average of $4.57 and a 200 day simple moving average of $7.54. Aptose Biosciences has a 52 week low of $2.39 and a 52 week high of $51.61. The stock has a market cap of $7.11 million, a price-to-earnings ratio of -1.12 and a beta of 1.14.

Institutional Trading of Aptose Biosciences

A hedge fund recently bought a new position in Aptose Biosciences stock. Bleichroeder LP bought a new position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 2,500,000 shares of the biotechnology company’s stock, valued at approximately $563,000. Bleichroeder LP owned 4.15% of Aptose Biosciences at the end of the most recent reporting period. 26.62% of the stock is currently owned by institutional investors.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.